ONdrugDelivery - ONdrugDelivery - drug delivery industry specialised b2b information

MEETING THE NEED FOR HIGH-VOLUME DRUG DELIVERY WITH ON-BODY BOLUS INJECTORS

E3D Managing Director and Chief Business Officer Tsachi Shaked shows how on-body injectors present a safe and viable solution for high-volume drug delivery.

EASING PATIENT EXPERIENCE WITH INNOVATIVE LARGE-VOLUME WEARABLES

Victoria Morgan discusses the growing sector of wearable injectors, with a specific focus on West’s own SmartDose^® injector and the value of fill-finish services.

THE NEW PATIENT-CENTRICITY

Jennifer Estep discusses the new pressures put on the healthcare system by the covid-19 pandemic, and how patients and healthcare providers alike are turning to patient-centric solutions to minimise risks and ease burdens.

WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS

WEARABLE INJECTORS: LATEST DEVICES & RECENT TRENDS

Wearable injection device expert Tom Oakley discusses recent trends in the space. He also takes a look at wearable injection devices currently on the market and considers the future of wearable injectors.

STABILITY OF A WEARABLE INJECTOR POWERED BY OSMOSIS

STABILITY OF A WEARABLE INJECTOR POWERED BY OSMOSIS

Jesper Roested and Tomas Gundberg present engineering test data on Subcuject’s wearable bolus injector, based on an osmotic drive system, demonstrating that the device presents a solution to the need for an inexpensive, mass-producible wearable injector.

ANDREI YOSEF, CEO, SORREL MEDICAL

Dr Andrei Yosef

ANDREI YOSEF, CEO, SORREL MEDICAL

In this exclusive interview, Andrei Yosef discusses Sorrel’s differentiated electro-mechanical, connected wearable injection platform, and two exciting recent milestones for the company, the opening of a state-of-the-art manufacturing facility and the signing of a significant partnership with a large pharma company.

EMERGING TRENDS IN WEARABLE DRUG DELIVERY

Phillips-Medisize

EMERGING TRENDS IN WEARABLE DRUG DELIVERY

Tony Bedford discusses the current state of the fledgling on-body injector market, including the difficulties of competing with autoinjectors in the <5 mL space, the potential on-body injectors have in oncology and Phillips-Medisize’s own developments in the on-body injector field.

SIMPLIFYING LARGE-VOLUME PATCH INJECTION FOR PHARMA AND PATIENTS

SIMPLIFYING LARGE-VOLUME PATCH INJECTION FOR PHARMA AND PATIENTS

Reto Jost provides an update on the YpsoDose platform and its importance as the driver for the business unit’s new patch injector franchise.

TECHNOLOGY SHOWCASE: CCBio’s QuickDose

TECHNOLOGY SHOWCASE: CCBio’s QuickDose

CCBio is introducing a new era of wearable on-body medical devices. QuickDose, recently successfully developed with both patients and pharmaceutical industry partners in mind, contains all the necessary elements for an excellent on-body device, comprising three major technical achievements.

OPTIMA COVID-19 VACCINE FILLING SYSTEM DELIVERED TO CATALENT IN THE US

OPTIMA COVID-19 VACCINE FILLING SYSTEM DELIVERED TO CATALENT IN THE US

Optima has delivered a second vial filling system to Catalent's biologics facility in Bloomington, IN, US, to be used initially for the filling of a vaccine candidate to fight Covid-19 (SARS-CoV-2).

INNOVATION AND AUTOMATION IN TOPICAL FORMULATION DEVELOPMENT

INDUSTRIALISATION

Prof Marc Brown

INNOVATION AND AUTOMATION IN TOPICAL FORMULATION DEVELOPMENT

Marc Brown, Jon Lenn and Charles Evans discuss the challenges faced by the pharmaceutical industry during the development of topical delivery formulations, and how MedPharm’s performance testing models help identify and mitigate risks during the process.

FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES

INDUSTRIALISATION

FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES

Stephen Allan reviews the history and formulation advantages of lipid nanoparticles (LNPs) and addresses factors that should be considered by pharmaceutical companies during the CDMO selection process to help reduce regulatory risk, improve product performance and accelerate speed to market.

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

INTERVIEW WITH AARON MANN, CHIEF EXECUTIVE OFFICER, KINDEVA

In this exclusive interview with ONdrugDelivery, Aaron Mann discusses how Kindeva is positioned to move forward as a major CDMO specialising in inhalation and transdermal dosage forms, having been formed from 3M’s drug delivery in May 2020. We also cover the impact of Covid-19, environmental sustainability, and current challenges faced by the pharmaceutical industry.

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE

Frédérique Bordes-Picard

ADVANCED CAPSULE TECHNOLOGIES: DRY POWDER INHALERS TO TARGET DISEASE

Frédérique Bordes-Picard and Julien Lamps discuss the value of capsule-based dry powder inhalers in the modern respiratory market, the factors driving development in this area and considerations for matching a capsule to a device and formulation.

CUSTOMISING PLATFORM DEVICES: CHALLENGES & CONSIDERATIONS

INDUSTRIALISATION

CUSTOMISING PLATFORM DEVICES: CHALLENGES & CONSIDERATIONS

How do you choose the best delivery system for your drug? Doug Boyd explores the pros and cons of a cost-effective, off-the-shelf platform versus a custom drug delivery device, and discusses the challenges and considerations of customising an existing platform device.

MEETING QUALITY DEMANDS THROUGH INTEGRATED PRODUCTS & SERVICES

INDUSTRIALISATION

Lars Keinicke Hansen

Stevanato Group

MEETING QUALITY DEMANDS THROUGH INTEGRATED PRODUCTS & SERVICES

Lars Keinicke Hansen; Chiara Mussoi and Odra Pinato describe how the streamlining of processes and harmonisation of products and services can better serve pharmaceutical companies. A case study highlights how a unique combination of expertise in automation and glass primary packaging benefited pharma giant Merck Serono in a recent project.

MEETING DEMAND BY BRINGING MANUFACTURING IN-HOUSE

INDUSTRIALISATION

MEETING DEMAND BY BRINGING MANUFACTURING IN-HOUSE

Bentsi Algazi and Anna Kalika-Rodin discuss the process of developing and implementing in-house production facilities at Sorrel Medical, including cleanroom facilities. The authors discuss the regulatory requirements involved, practical considerations of the design and construction, and the benefits the establishment of in-house facilities confers to Sorrel and its pharmaceutical partners.

APPLICATIONS OF DEEP LEARNING IN MEDICAL DEVICE MANUFACTURING

INDUSTRIALISATION

Frederick Gertz

APPLICATIONS OF DEEP LEARNING IN MEDICAL DEVICE MANUFACTURING

Frederick Gertz and Gilbert Fluetsch look at how deep learning can be leveraged in a medical device manufacturing environment.

THE FUTURE OF SMART FILL-AND-FINISH

INDUSTRIALISATION

THE FUTURE OF SMART FILL-AND-FINISH

Diana Löber discusses new developments in digitised pharmaceutical manufacturing and the role SCHOTT’s Smart Containers can play in traceability along the entire value chain.

VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

VAXESS RECEIVES BARDA CONTRACT FOR COVID-19 + SEASONAL FLU VACCINE IN ITS SMART-RELEASE MICRONEEDLE PATCH

Vaxess Technologies is to receive US BARDA funding to demonstrate the feasibility of its MIMIX microneedle patch technology for a COVID-19 vaccine, with the aim of designing and developing a “combination seasonal protection patch”, incorporating COVID-19 + seasonal influenza protection.

TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19

TFF AND UNION AGREE LICENSING PACT FOR TFF TECHNOLOGY WITH NICLOSAMIDE FOR THE TREATMENT OF COVID-19

UNION therapeutics has acquired an option to a worldwide, exclusive licence to TFF Pharmaceuticals' Thin Film Freezing (TFF) technology, in combination with niclosamide, covering oral and inhalation formulations, potentially for COVID-19, as well as other niclosamide-based therapies.

THE FLOWABILITY OF LACTOSE POWDERS TO OPTIMISE TABLETING PROCESSES

Dr Aurelien Neveu

THE FLOWABILITY OF LACTOSE POWDERS TO OPTIMISE TABLETING PROCESSES

Aurélien Neveu, Pauline Janssen and Geoffroy Lumay discuss how new measurement methods can help gain a better understanding of the flowability of lactose powders – a necessary step for future improvement of oral delivery systems.

NANOPARTICLE ENGINEERING: REVOLUTIONISING ORAL DRUG DEVELOPMENT & DELIVERY

NANOPARTICLE ENGINEERING: REVOLUTIONISING ORAL DRUG DEVELOPMENT & DELIVERY

Satu Lakio and Niklas Sandler discuss the benefits of nanoparticle engineering technology as a means of improving the bioavailability and solubility of drug compounds.

TECHNOLOGY SHOWCASE: Röchling Medical’s Sympfiny<sup>®</sup>

Röchling Medical

TECHNOLOGY SHOWCASE: Röchling Medical’s Sympfiny^®

Röchling Medical presents Sympfiny®, an innovative system for dosing and delivering multiparticulate, dry powder, and microsphere drug formulations for oral delivery, which it developed In collaboration with HS Design.

AN EASY PILL TO SWALLOW

AN EASY PILL TO SWALLOW

Kelly Boyer and Ali Rajabi-Siahboomi explore the role of different tablet coating materials in improving the patient experience and adherence to prescription regimens.

INTERVIEW WITH MARIA FLYNN, ADARE PHARMACEUTICALS

Adare Pharmaceuticals

INTERVIEW WITH MARIA FLYNN, ADARE PHARMACEUTICALS

Adare Pharma's Maria Flynn talks with ONdrugDelivery about trends in the oral drug development and delivery space, completing the Orbis Biosciences acquisition during a global pandemic, and how the excellent technology portfolio and strategic fit between Orbis and Adare form part of the combined organisation’s unique story.

INNOVATIONS IN 3D PRINTED PHARMACEUTICALS

Sarah Trenfield

INNOVATIONS IN 3D PRINTED PHARMACEUTICALS

Sarah Trenfield, Abdul Basit and Alvaro Goyanes discuss the latest innovations in 3D printed pharmaceuticals.

RECENT DEVELOPMENT IN COMPLEX TABLET FORMULATION DESIGN FOR VERSATILE APPLICATIONS

Dr Mathieu Degomme

Skyepharma Production

RECENT DEVELOPMENT IN COMPLEX TABLET FORMULATION DESIGN FOR VERSATILE APPLICATIONS

Mathieu Degomme and Aline Moulin outline three case studies from recent early-stage development programmes to illustrate what kind of complex tablets can be developed to meet specific target dissolution profiles for versatile applications.

THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS

María Fernández-Martos Balson

THE RISE OF COMPLEX ORAL DELIVERY SYSTEMS

María Fernández-Martos Balson and Bastiaan De Leeuw explore the oral delivery of biologics and the challenges that must be overcome in order to enhance bioavailability. The authors also take a look at some recently developed drug-device combinations.

OPTICORE™: A FIRST-IN-CLASS COLONIC TARGETING TECHNOLOGY

Dr Felipe Varum

Tillotts Pharma

OPTICORE™: A FIRST-IN-CLASS COLONIC TARGETING TECHNOLOGY

Felipe Varum, Roberto Bravo and Abdul Basit discuss the use of colonic targeting coating technology OPTICORE™ to deliver APIs in the treatment of ulcerative colitis (UC) patients.

INTERVIEW WITH MILENA BATALLA, PHD, PANARUM

INTERVIEW WITH MILENA BATALLA, PHD, PANARUM

Dr Batalla introduces the company and describes its Proteoral^® technology for the oral delivery of proteins to the bloodstream, therapeutic applications, and products to date. Panarum is an Argentine company and this interview is presented here in Spanish and English, an exciting first for ONdrugDelivery!

UNIQUE MINITABLET DISPENSER MEETS FLEXIBLE ORAL DOSING NEED

Bjørn Knud Andersen

Phillips-Medisize

UNIQUE MINITABLET DISPENSER MEETS FLEXIBLE ORAL DOSING NEED

Bjørn Knud Andersen discusses how an innovative minitablet dispenser that mounts on a standard medication container simply and effectively meets the growing needs of patients in paediatrics, geriatrics, oncology and other areas who require reliable customised oral dosing.

COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?

Napoleon Monroe

COVID-19: A CATALYST FOR IMPLEMENTING CONNECTED HEALTHCARE PRODUCTS?

Napoleon Monroe analyses how COVID-19 is catalysing a wide range of reactions in healthcare, explaining how drug and device connectivity are essential to improving patient access to treatment – and patient outcomes – as well as reducing overall cost.

THE AWARD-WINNING CREDENCE CONNECT™ AUTO-SENSING INJECTION SYSTEM

Credence MedSystems

THE AWARD-WINNING CREDENCE CONNECT™ AUTO-SENSING INJECTION SYSTEM

John Merhige explains how connectivity that is universally applicable to any existing prefilled syringe platform adds value throughout the ecosystem, both including and beyond the “compliance business model”.

POLYMERIC EMI SHIELDING: PROVIDING A MORE SECURE FUTURE FOR PATIENTS

POLYMERIC EMI SHIELDING: PROVIDING A MORE SECURE FUTURE FOR PATIENTS

Marnik Vaes, Leen-Pieter Deurloo and Martin Sas discuss the role of polymeric electromagnetic interference shielding in providing a more secure future for patients in a connected world.

SENSORS ARE TOOLS – BUT HOW DO YOU MAKE THEM SMART?

SENSORS ARE TOOLS – BUT HOW DO YOU MAKE THEM SMART?

Gaël Senée and Arnaud Guillet explore the benefits of Mallya – a smart sensor that turns conventional injection pens into connected devices. They also discuss the crucial role Biocorp’s connected prefilled syringe, Injay, could play in future COVID-19 vaccination programmes.

RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES

RISKS AND REAL-WORLD SOLUTIONS FOR CONNECTED MEDICAL DEVICES

Tom Oakley discusses the risks surrounding the use of connected drug delivery devices – and the real-world solutions that have either been proved or are being trialled.

APPLYING CONNECTIVITY TO ENHANCE THE TRAINING STANDARD OF CARE FOR SELF-INJECTION

APPLYING CONNECTIVITY TO ENHANCE THE TRAINING STANDARD OF CARE FOR SELF-INJECTION

Erin Miller looks at how connectivity can be used to enhance training to help address the challenges of accuracy and non-adherence when patients self-inject their medications.

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES

Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.

1
2
3
…
22
Next

See what ondrugdelivery's readers and contributors think

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.